SKC podcast

From genes to therapies - Decades of commitment to rare diseases

Thu, 2024 / 02 / 29
In the first episode of our second profcast series, Prof Dr Matthias P. Schönermark talks with Prof Dr med Annette Grüters-Kieslich, chairwoman of the Eva Luise and Horst Köhler foundation.

They talk about the challenges and successes in the diagnosis and treatment of rare diseases as well as the importance of networks and research. Our guest particularly vividly explains the decades of therapy development using the example of rare congenital metabolic diseases.

You can find Profcast From genes to therapies - Decades of commitment to rare diseases on Spotify and Apple Podcast (in German language only). Tune in!

Please click to load Contents from Personal data may be transferred to the provider.

About the Profcast

Our SKC podcast series "The Profcast - rare diseases and their therapies" aims to address the special circumstances of patients with rare diseases, the associated medicine and the challenges for research, development, economics and reimbursement. For this purpose, Prof. Matthias P. Schönermark, M.D., Ph.D., managing director of SKC, speaks with patient representatives, payers, clinicians and scientists as well as industry representatives and also focuses on specific diseases. The word Profcast is a reference to professionals or professors, whom he welcomes as his guests.

The ambition behind this is to give an appropriate space to rare diseases and their treatment sine ira et studio. After all, the motto of the Rare Disease Day states it so aptly: "Rare is many". It is estimated that 4 million people in Germany and 300 million people worldwide are affected by a rare disease. In keeping with the Rare Disease Day, which traditionally takes place on the last day of February, the Profcast is published on the last day of a month.


About the author

Ihr Ansprechpartner Univ.-Prof. Dr. med. Matthias P. Schönermark
Univ.-Prof. Dr. med. Matthias P. Schönermark
Gründer und Geschäftsführer
Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 18

AMNOG orphan tracker

In our orphan tracker, we examine ongoing AMNOG procedures for orphan drugs.

EU HTA: European Health Technology Assessment (JCA)

Achieve planning security: With us you can align your projects and your resource planning comprehensively and at an early stage on EU HTA and its implications for market access.

Negotiation support

Actively shaping the success of negotiations
to the top